Where does compounded semaglutide API come from? FDA import records by country

Where does compounded semaglutide API come from?

FDA’s import records show where semaglutide API offered for U.S. import was made, not which pharmacy used it. The Green List of FDA’s Import Alert 66-80 (published Oct 9, 2026) has 10 entries naming semaglutide: China (7), Belgium (1), Denmark (1) and Portugal (1), with the firm names redacted by FDA. FDA’s import refusal files (Jan 1, 2002 to Oct 30, 2026) list 11 refused lines with a semaglutide API or powder product code, from China (11), among 501 refused semaglutide lines in all.

Records read Nov 15, 2026. Import Alert 66-80 is FDA’s import alert for GLP-1 bulk drug substances; its own text says that during the shortages, “APIs used to compound GLP-1 drug products were supplied by various API manufacturers located around the world, including China, India, and Europe.”

Green List entries naming semaglutide, by country

CHINA7
BELGIUM1
DENMARK1
PORTUGAL1
Product codes and drugs listed
1Redacted by FDABELGIUM61P[][]72 Semaglutide (Anti-Diabetic)
61P[][]75 Exenatide (Anti-Diabetic)
4Redacted by FDACHINA56F[][]99 Peptide N.E.C. (Antibiotics)
61P[][]72 Semaglutide (Anti-Diabetic)

61P[][]99 Anti-Diabetic N.E.C. (Anti-Diabetic)
5Redacted by FDACHINA61P[][]76 Liraglutide (Anti-Diabetic)
61P[][]72 Semaglutide (Anti-Diabetic)

61P[][]74 Tirzepatide (Anti-Diabetic)
7Redacted by FDACHINA61P[][]76 Liraglutide (Anti-Diabetic)
61P[][]72 Semaglutide (Anti-Diabetic)

61P[][]74 Tirzepatide (Anti-Diabetic)
8Redacted by FDACHINA61P[][]76 Liraglutide (Anti-Diabetic)
61P[][]72 Semaglutide (Anti-Diabetic)

61P[][]74 Tirzepatide (Anti-Diabetic)
10Redacted by FDACHINA61P[][]76 Liraglutide (Anti-Diabetic)
61P[][]72 Semaglutide (Anti-Diabetic)

61P[][]74 Tirzepatide (Anti-Diabetic)
12Redacted by FDACHINA61P[][]72 Semaglutide (Anti-Diabetic)
61P[][]74 Tirzepatide (Anti-Diabetic)
13Redacted by FDACHINA61P[][]76 Liraglutide (Anti-Diabetic)
61P[][]72 Semaglutide (Anti-Diabetic)

61P[][]74 Tirzepatide (Anti-Diabetic)
15Redacted by FDADENMARK61P[][]76 Liraglutide (Anti-Diabetic)
61P[][]72 Semaglutide (Anti-Diabetic)
20Redacted by FDAPORTUGAL61P[][]72 Semaglutide (Anti-Diabetic)
61P[][]77 Orforglipron SDD (Anti-Diabetic)

Refused semaglutide API or powder lines, by country

A line counts here when its FDA product code is one Import Alert 66-80 lists as a semaglutide API or powder form (process indicator codes the alert describes as “Active Pharm Ingred/Chems for Further Manuf”, “Active Pharm Ingred/Chems for Rx Compounding”, “NonSterile Powder” or “Sterile Powder”).

China11
FDA refusal chargesShipment ID
Oct 7, 2026XU LIHUA JINGFANG Trading Co. LTDChina61PIR72 SEMAGLUTIDE (ANTI-DIABETIC)NonSterile PowderLACKS FIRM: The article is in package form and appears to not bear a label containing the name and place of business of the manufacturer, packer, or distributor.
INCONSPICU: Information required by the Act to be on the label or labeling does not appear to be conspicuous enough as to render it likely to be read and understood by the ordinary individual under customary conditions of purchase and use.

WARNINGS: It appears to lack adequate warning against use in a pathological condition or by children where it may be dangerous to health or against an unsafe dose, method, administering duration, application, in manner/form, to protect users.

DRUG NAME: The article appears to be a drug and fails to bear the proprietary or established name and/or name and quantity of each active ingredient.
XXX-0763336-3/1/4
May 19, 2026NANJING HANXIN INTERNATIONALChina61PCT72 SEMAGLUTIDE (ANTI-DIABETIC)Active Pharm Ingred/Chems for Rx CompoundingDIRSEXMPT: The article is subject to refusal of admission pursuant to Section 801(a)(3) in that it appears to be a drug within the meaning of Section 201(g) and it lacks adequate directions for use.
FALSEDRUG: The article is subject to refusal of admission pursuant to Section 801(a)(3) in that it appears to be a drug which is misbranded within the meaning of section 502(a)(1) in that its labeling is false or misleading.
1FX-1577805-2/10003/1
May 14, 2026Hybio Pharmaceutical (Wuhan) Co., Ltd.China61PCT72 SEMAGLUTIDE (ANTI-DIABETIC)Active Pharm Ingred/Chems for Rx CompoundingNOT LISTED: The article is subject to refusal of admission pursuant to section 801(a)(3) of the FD&C Act in that it appears to be misbranded as defined in section 502(o) of the FD&C Act. Based on the information available to the FDA, it appears that the drug or device is not included in a list required by Section 510(j), or a notice or other information respecting it was not provided as required by 510(j) or 510(k).
DIRSEXMPT: The article is subject to refusal of admission pursuant to Section 801(a)(3) in that it appears to be a drug within the meaning of Section 201(g) and it lacks adequate directions for use.

FRNMFGREG: The article is subject to refusal of admission pursuant to section 801(a)(3) in that it appears to be misbranded as defined in section 502(o) of the FD&C Act. Based on information available to FDA, it appears that it was manufactured, prepared, propagated, compounded, or processed in an establishment not duly registered under Section 510 of the Act.
8NP-0144593-5/10002/1
Aug 6, 2025Harbin Jixianglong Biotech Co., Ltd.China61PCT72 SEMAGLUTIDE (ANTI-DIABETIC)Active Pharm Ingred/Chems for Rx CompoundingDIRSEXMPT: The article is subject to refusal of admission pursuant to Section 801(a)(3) in that it appears to be a drug within the meaning of Section 201(g) and it lacks adequate directions for use.H77-0229191-2/13/1
May 1, 2025Hangzhou ThinHeal Pharma-Tech Co., Ltd.China61PCT72 SEMAGLUTIDE (ANTI-DIABETIC)Active Pharm Ingred/Chems for Rx CompoundingNOT LISTED: The article is subject to refusal of admission pursuant to section 801(a)(3) of the FD&C Act in that it appears to be misbranded as defined in section 502(o) of the FD&C Act. Based on the information available to the FDA, it appears that the drug or device is not included in a list required by Section 510(j), or a notice or other information respecting it was not provided as required by 510(j) or 510(k).
FRNMFGREG: The article is subject to refusal of admission pursuant to section 801(a)(3) in that it appears to be misbranded as defined in section 502(o) of the FD&C Act. Based on information available to FDA, it appears that it was manufactured, prepared, propagated, compounded, or processed in an establishment not duly registered under Section 510 of the Act.
BYA-2501606-4/12/1
Oct 28, 2024Fujian Genohope Biotech LtdChina61PCS72 SEMAGLUTIDE (ANTI-DIABETIC)Active Pharm Ingred/Chems for Further ManufNOT LISTED: The article is subject to refusal of admission pursuant to section 801(a)(3) of the FD&C Act in that it appears to be misbranded as defined in section 502(o) of the FD&C Act. Based on the information available to the FDA, it appears that the drug or device is not included in a list required by Section 510(j), or a notice or other information respecting it was not provided as required by 510(j) or 510(k).
FRNMFGREG: The article is subject to refusal of admission pursuant to section 801(a)(3) in that it appears to be misbranded as defined in section 502(o) of the FD&C Act. Based on information available to FDA, it appears that it was manufactured, prepared, propagated, compounded, or processed in an establishment not duly registered under Section 510 of the Act.
AEK-5719160-1/11/1
Jan 25, 2024Qingdao Biopeptek Co., Ltd.China61PCR72 SEMAGLUTIDE (ANTI-DIABETIC)NonSterile PowderLACKS FIRM: The article is in package form and appears to not bear a label containing the name and place of business of the manufacturer, packer, or distributor.
DIRSEXMPT: The article is subject to refusal of admission pursuant to Section 801(a)(3) in that it appears to be a drug within the meaning of Section 201(g) and it lacks adequate directions for use.
AEK-3647198-3/11/1
Dec 6, 2023Qingdao Biopeptek Co., Ltd.China61PCT72 SEMAGLUTIDE (ANTI-DIABETIC)Active Pharm Ingred/Chems for Rx CompoundingLACKS FIRM: The article is in package form and appears to not bear a label containing the name and place of business of the manufacturer, packer, or distributor.
DIRSEXMPT: The article is subject to refusal of admission pursuant to Section 801(a)(3) in that it appears to be a drug within the meaning of Section 201(g) and it lacks adequate directions for use.

FALSEDRUG: The article is subject to refusal of admission pursuant to Section 801(a)(3) in that it appears to be a drug which is misbranded within the meaning of section 502(a)(1) in that its labeling is false or misleading.
AEK-3571990-3/11/1
Oct 11, 2023Zhejiang Peptites Biotech Co.,Ltd.China61PDT72 SEMAGLUTIDE (ANTI-DIABETIC)Active Pharm Ingred/Chems for Rx CompoundingDIRSEXMPT: The article is subject to refusal of admission pursuant to Section 801(a)(3) in that it appears to be a drug within the meaning of Section 201(g) and it lacks adequate directions for use.906-0395480-4/11/1
Sep 27, 2023Zhejiang Peptites Biotech Co.,Ltd.China61PDT72 SEMAGLUTIDE (ANTI-DIABETIC)Active Pharm Ingred/Chems for Rx CompoundingDIRSEXMPT: The article is subject to refusal of admission pursuant to Section 801(a)(3) in that it appears to be a drug within the meaning of Section 201(g) and it lacks adequate directions for use.8V8-0000195-1/11/2
Sep 7, 2023Zhejiang Peptites Biotech Co.,Ltd.China61PCT72 SEMAGLUTIDE (ANTI-DIABETIC)Active Pharm Ingred/Chems for Rx CompoundingDIRSEXMPT: The article is subject to refusal of admission pursuant to Section 801(a)(3) in that it appears to be a drug within the meaning of Section 201(g) and it lacks adequate directions for use.8GX-8000731-3/11/1

All refused semaglutide lines, by form

490 of the 501 refused semaglutide lines carry a product code that Import Alert 66-80 does not list as an API or powder form. The form column uses the alert’s own wording where the alert lists the code.

Code not listed on Import Alert 66-80490
Active Pharm Ingred/Chems for Rx Compounding8
NonSterile Powder2
Active Pharm Ingred/Chems for Further Manuf1
Canada208
Denmark149
United States26
China19
Colombia17
United Kingdom15
India14
Mexico11
Brazil9
Bangladesh5
Germany4
Singapore4
France3
Hong Kong2
Israel2
Japan2
Nigeria2
Albania1
Bulgaria1
Egypt1
Greece1
Honduras1
Indonesia1
Italy1
Philippines1
Turkey1

What these records do not show

FDA prints a redaction in place of every firm name on the Import Alert 66-80 Green List, so the list shows countries and drugs, not companies. Import refusals record shipment lines FDA refused, not shipments it admitted, and they do not say which pharmacy or other buyer the API was meant for. Neither record says which supplier a given pharmacy uses.

Firms named on refused lines: Firms on GLP-1 import records.

Common questions

Does FDA publish which companies are on the GLP-1 API Green List?

The Import Alert 66-80 page lists 21 Green List entries with country and product codes, and prints a redaction in place of each firm name (read Nov 15, 2026).

Which countries are on the Green List for semaglutide?

China (7), Belgium (1), Denmark (1) and Portugal (1), as of the alert published Oct 9, 2026.

What does a refusal record show?

That FDA refused admission of one shipment line, with the charges FDA cited. It is not a test result unless the line is marked for FDA sample analysis.

This page lists public regulatory records as published by the issuing agency. A record is not a finding by this site. A warning letter states the agency’s view at the time it was issued; companies may have responded or corrected the issue since. Follow each link for the original document and any close-out letter. Report an error or add a company response.

Sources

Records last pulled Nov 15, 2026. Every entry links to the original public record.